No­var­tis strikes $250M buy­out for Mer­ck Serono spin­out's au­toim­mune 'pipeline-in-a-drug'

No­var­tis is set to ac­quire au­toim­mune-fo­cused Ca­lyp­so Biotech for $250 mil­lion up­front, lay­ing claim to the first phar­ma buy­out of 2024 just hours be­fore the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.